首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
【24h】

TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.

机译:TLR9 / TLR7触发了健康个体和狼疮患者的人浆细胞样树突细胞上BDCA2表达的下调。

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmacytoid dendritic cells (pDCs) can produce a large amount of interferon-alpha (IFN-alpha) upon exposure to TLR9 or TLR7 agonists. Human pDCs have been shown to play an important role in the pathogenesis of systemic lupus erythematosus (SLE) through increased production of IFN-alpha. So, how to negatively regulate activation of pDCs and how to evaluate the activation of pDC in SLE patients attract much attention. BDCA2 is selectively expressed on human pDCs, acting as a hallmark of human pDCs. In this study, we showed that BDCA2 expression on pDCs decreased along maturation of pDCs, and TLR7 or TLR9 agonists could further significantly downregulate pDCs to express BDCA2, suggesting that the activated pDCs exhibit decreased expression of BDCA2. Functionally, BDCA2 ligation significantly inhibited upregulation of CD40, CD86 and CCR7 expression, IFN-alpha, IFN-beta and IL-6 production by pDCs stimulated with CpG ODN. Moreover, BDCA2 ligation suppressed CpG ODN-activated pDCs to mediate Th1 response, including T cell proliferation, IFN-gamma production, and CD4(+)CCR5(+)Th1 development, confirming that BDCA2 is a negative regulator of TLR9-dependent activation of human pDCs. BDCA2 expression on pDCs from SLE patients decreased significantly but IFN-alpha production of these patients increased markedly as compared to that from healthy donors. Therefore, these results suggest that downregulation of BDCA2 expression on pDCs may reflect the activation of pDCs accumulated in SLE patients, and may be one marker for indication of the disease activity of SLE patients.
机译:浆细胞样树突状细胞(pDC)暴露于TLR9或TLR7激动剂后会产生大量干扰素-α(IFN-α)。已显示人类pDC通过增加IFN-α的产生在系统性红斑狼疮(SLE)的发病机理中发挥重要作用。因此,如何在SLE患者中负调节pDC的激活以及如何评估pDC的激活备受关注。 BDCA2在人pDC上选择性表达,是人pDC的标志。在这项研究中,我们表明pDC上的BDCA2表达随着pDC的成熟而降低,而TLR7或TLR9激动剂可能进一步显着下调pDC来表达BDCA2,这表明激活的pDC表现出BDCA2的表达降低。在功能上,BDCA2连接显着抑制了用CpG ODN刺激的pDC的CD40,CD86和CCR7表达,IFN-α,IFN-β和IL-6的上调。此外,BDCA2连接抑制CpG ODN激活的pDC介导Th1反应,包括T细胞增殖,IFN-γ产生和CD4(+)CCR5(+)Th1发育,证实BDCA2是TLR9依赖性激活TLR9的负调控因子。人类pDC。与健康供体相比,SLE患者的pDC上的BDCA2表达显着降低,但这些患者的IFN-α产生显着增加。因此,这些结果表明pDC上BDCA2表达的下调可能反映了SLE患者体内积累的pDC的激活,并且可能是指示SLE患者疾病活动的一种标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号